GlassScriptPhysician profile
William Sterling Sessions
NPI 1073004883
$585.13
in general payments reported to CMS, 2019-2025
9 companies · $50.59 in 2025
The $50.59 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $24.91 · 2023: $74.04 · 2024: $317 · 2025: $50.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $146.87 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Genentech USA, INC. | $118.21 | 2021 | |
| United Therapeutics Corporation | $113.39 | 2023-2025 | Tyvaso, Tyvaso, Remodulin |
| Merck Sharp & Dohme LLC | $58.40 | 2024 | Zerbaxa, Recarbrio |
| Edwards Lifesciences Corporation | $55.85 | 2022-2024 | Hemosphere |
| Becton, Dickinson and Company | $30.84 | 2024 | Hemosphere |
| Electromed, INC. | $29.08 | 2024 | Smartvest |
| Baxter Healthcare | $18.16 | 2023 | Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $14.33 | 2023 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sessions listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.